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Association between cigarette smoking and release of
tumour necrosis factor a and its soluble receptors by
peripheral blood mononuclear cells in patients with
rheumatoid arthritis
J. R. Glossop1,2, P. T. Dawes1 and D. L. Mattey1,2
Objective. To investigate the relationship between cigarette smoking and release of TNF-a and its soluble receptors (sTNFRI
and sTNFRII) by peripheral blood mononuclear cells (PBMCs) from RA patients.
Methods. We studied 71 RA patients with established disease (mean duration 10.6 yr). Smoking history was established by
questionnaire. T lymphocytes and monocytes were isolated from peripheral blood and incubated with or without stimulation
(phytohaemagglutinin and lipopolysaccharide, respectively). Release of TNF-a and sTNFR into culture medium was measured
by enzyme-linked immunosorbent assay.
Results. TNF-a release by stimulated T lymphocytes was signiﬁcantly higher in patients with a history of smoking than in
those who had never smoked (1416.0 vs 767.4 pg/ml, P¼ 0.04), and showed a relationship with smoking duration and intensity
(P for trend 0.009). Monocyte TNF-a release was not associated with smoking status. Release of sTNFR showed no clear
relationships with extent of smoking, although release by stimulated T lymphocytes was higher in past smokers than in those
who had never smoked (P 0.03). The ratio of TNF-a/sTNFR released from T lymphocytes was higher in past and current
smokers, and was associated with extent of smoking. No relationship was found between smoking and plasma TNF-a levels,
but levels of both receptors were higher in past smokers.
Conclusion. In RA patients who smoke there is an alteration in the ratio of TNF-a/sTNFR released by stimulated T cells that
might favour increased TNF-a activity. The increased TNF-a/sTNFR ratio is associated with extent of smoking, and remains
elevated after smoking cessation.
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Rheumatoid arthritis (RA) is a systemic autoimmune disease
characterized by chronic inﬂammation of the synovial joints,
ultimately leading to joint destruction and permanent disability.
Its precise aetiology remains to be elucidated, although both
environmental and genetic components are believed to inﬂuence
the development of disease. Of the former, cigarette smoking
appears to be of importance in both disease susceptibility and
severity.
A study of disease-discordant twins by Silman et al. [1] identiﬁed
an association between ever smoking and RA in both monozygotic
and dizygotic twin pairs. The results of other studies also indicate
that smoking might be a susceptibility factor in RA [2–7], and that
it is associated with more severe disease [7–14]. Most of these
studies have reported an association between smoking and the
incidence of rheumatoid factor (RF), suggesting that the effects of
smoking in RA might be mediated via RF production. More
recently, an interaction between smoking and carriage of the HLA-
DRB1 shared epitope has been reported to increase the risk of
developing RF positive RA [15].
The mechanisms responsible for the inﬂuence of smoking in
RA are not clear, although it seems reasonable to implicate toxic
compounds in cigarette smoke, such as nicotine and reactive
oxygen species. This might explain, at least in part, the ﬁnding
of altered immune cell functions in heavy smokers [16–18]. The
consequence of such changes may include effects on cytokine
secretion, since TNF- production by peripheral blood mono-
nuclear cells (PBMCs) is elevated in smokers [19, 20]. Lei et al. [20]
further showed that nicotine was capable of inducing increased
TNF- release. However, the effect of nicotine does not appear
to be simply inductive since nicotine at higher concentrations
inhibited TNF- secretion. Similarly, Madretsma et al. [21]
reported that nicotine, at levels equivalent to those in the plasma
of smokers, inhibited TNF- production in non-adherent
mononuclear cells.
TNF- is considered to be a central cytokine in RA inﬂamma-
tion [22], so evidence that components of cigarette smoke may
inﬂuence the release of TNF- implicates smoking as an important
factor in the inﬂammatory process. The actions of TNF- are
mediated through binding to two different cell surface receptors,
TNF receptor (TNFR) I and TNFRII [23, 24]. Both are
transmembrane glycoproteins with a conserved cysteine-rich
extracellular domain that facilitates ligand binding. The two
receptors can promote distinct TNF- -induced cellular responses,
although both are able to induce the NF-B and apoptotic
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pathways [25–29]. Both TNFRI and TNFRII can be shed from
cells as soluble proteins, derived from the receptor extracellular
domains [30–34] by the actions of TNF- converting enzyme
(TACE) or serine proteases such as elastase [35, 36]. Ligand
binding capacity is retained in this form and they can act as natural
inhibitors of TNF-. A recent study from our laboratory suggested
that the level of soluble TNFR (sTNFR) released by T cells from
RA patients is associated with polymorphism (T676G) in the
TNFRII gene [37].
In this study we investigated the release of TNF- and sTNFR
from PBMCs of a group of RA patients who were past or current




A group of 71 patients with established RA were studied (Table 1).
The patients were all of Caucasian origin and resident in North
Staffordshire, UK. They satisﬁed the 1987 American College of
Rheumatology criteria for RA [38]. Each patient was receiving
anti-inﬂammatory and/or anti-rheumatic therapy. The majority
of patients (>95%) was being treated with one or more disease-
modifying anti-rheumatic drugs, whilst a small minority of
individuals (<5%) received steroids and cytotoxic drugs such as
azathioprine or cyclophosphamide. No patients were being treated
with anti-TNF- agents. The study was approved by the North
Staffordshire local research ethics committee, and all patients gave
written informed consent to participate.
Determination of smoking history
A history of current and past smoking was obtained from a
questionnaire completed by each patient. Patients were initially
classiﬁed by whether they had ever or never smoked. Ever smokers
were those that had smoked at least one cigarette a day for 1 yr or
more. All patients who had ever smoked had started smoking
before the onset of RA. Those who had ever smoked were further
categorized into past and current smokers. All past smokers had
stopped smoking at least 1 yr before entry into the study. The
extent of smoking was quantiﬁed in pack years. One pack year is
equivalent to 20 cigarettes per day for 1 yr. The demographic and
clinical characteristics of the smoking and non-smoking groups are
shown in Table 1. Consistent with other studies, patients with a
smoking history were more likely to be male [odds ratio (OR) 2.8,
95% conﬁdence interval (CI) 1.0–7.9, P¼ 0.049], and positive for
RF (OR 2.9, 95% CI 1.1–7.9). There was also a trend towards
increased frequency of nodular disease in smokers. No signiﬁcant
differences were seen between groups with regard to age of onset,
disease duration, Health Assessment Questionnaire (HAQ) score,
erosive disease and Larsen score, although past smokers were older
than current smokers (P¼ 0.048).
Cell isolation and culture
Fresh peripheral blood samples (22ml) were collected during the
morning from each patient. T lymphocytes were isolated from 4ml
blood by negative selection using a modiﬁed density gradient
centrifugation technique that uses novel tetrameric antibody
complexes (RosetteSep; Stemcell Technologies, Vancouver, BC,
Canada). Monocytes were isolated form 12ml blood using a
standard density gradient centrifugation method (NycoPrepTM
1.068; Nycomed Pharma AS Diagnostics, Oslo, Norway). Isolated
T lymphocytes (2 105 cells/200l) and monocytes (105 cells/
200l) were cultured in RPMI 1640 synthetic culture medium
supplemented with 10% heat-inactivated fetal bovine serum,
100 U/ml penicillin, 100g/ml streptomycin and 10% autologous
serum, in 96-well cell culture plates. T lymphocyte and monocyte
cultures were incubated, with or without phytohaemagglutinin
(PHA; 10g/ml) or lipopolysaccharide (LPS; 0.01g/ml), respec-
tively, at 378C in a 5% CO2 humidiﬁed air environment. Cell
supernatants were harvested after 24 (monocytes) and 48 h
(T lymphocytes) and were stored at –208C until required for
analysis of TNF- and sTNFR release.
Enzyme-linked immunosorbent assays (ELISAs)
The release of TNF- and sTNFR into the culture medium
by T lymphocytes and monocytes was quantiﬁed using the
respective Duoset ELISA Development Kit as directed by the
manufacturer (R&D Systems Europe, Abingdon, UK). For
determination of stimulated TNF- release, T lymphocyte and
monocyte samples were diluted 1:3 and 1:10, respectively, whilst all
unstimulated samples were diluted 1:2. To measure the release of
both soluble TNFRI and TNFRII, all T-lymphocyte samples were
diluted 1:3 and all monocyte samples were diluted 1:4. Levels of
TNF-, sTNFRI and sTNFRII were also measured in plasma
collected at the same time as the mononuclear cells. Plasma
samples were run undiluted, diluted 1:10 and diluted 1:20
respectively. All samples were run in duplicate with the appropriate
standards on 96-well microplates, and measured at a wavelength
of 450 nm.
Statistical analysis
Mononuclear cell release of TNF- and sTNFRs was compared
between smoking groups (never, past and current) by
Kruskal–Wallis one-way analysis of variance (ANOVA) for
TNF- levels, or analysis of covariance (ANCOVA) with adjust-
ment for age (where appropriate) for sTNFR levels. The extent of
smoking was also stratiﬁed into a number of categories according
to years smoked (duration) or pack years (intensity) (i.e. 0, 1–14,
15–29, 30), and general linear model (GLM) implementation of
ANOVA or ANCOVA was carried out to examine any relation-
ship with TNF- or sTNFR release. In all analyses, correction for
multiple comparisons was carried out by the Bonferroni (com-
parison with control) method. The relationships between cellular
release of TNF- and each soluble TNFR and their correlation
with age and disease duration were assessed by Spearman’s rank
correlation (non-parametric data) or Pearson’s correlation (nor-
mally distributed data) where appropriate. All data were analysed
using the Number Cruncher Statistical Software package for
Windows (NCSS 2000; NCSS Statistical Software, Kaysville,
UT, USA).







(n¼ 25) (n¼ 29) (n¼ 17)
Male/female (n) 6/19 15/14 7/10
Age, mean S.D. (yr) 53.0 (11.8) 54.3 (7.9) 48.7 (10.8)
Age at onset,
mean S.D. (yr)
43.0 (10.6) 42.5 (10.0) 39.3 (10.7)
Disease duration,
mean S.D. (yr)
10.0 (8.3) 11.7 (6.3) 9.4 (4.5)
RF-positive 40% 67.9% 64.7%
Nodule-positive 16% 27.6% 41.2%
Erosions 91.7% 96.0% 88.2%
HAQ score 1.24 1.45 1.43
Larsen score 78.7 87.9 78.0
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Smoking and mononuclear cell release of TNF-
Of the 71 patients, 17 (23.9%) were current smokers, 29 (40.8%)
were past smokers and the remaining 25 (35.2%) had never
smoked. The extent of smoking in past and current smokers was
similar, with no signiﬁcant difference in the mean number of pack
years (27.2 vs 26.5, respectively), although the current smokers
tended to have smoked for longer (25.1 vs 32.8 yr).
Release of TNF- by unstimulated T lymphocytes was
undetectable (<15pg/ml) in 44/69 (63.8%) patients, but detectable
in cells from all patients after stimulation. In the case of
monocytes, TNF- release was detected in unstimulated cells
from the majority of patients (77.6%) and in stimulated cells from
all patients. The amount of TNF- released from mononuclear cell
populations showed no relationship with age of patient or the
duration of disease.
Kruskal–Wallis ANOVA with correction for multiple compar-
isons revealed that stimulated T lymphocytes from past smokers
released signiﬁcantly more TNF- than did cells from patients
who had never smoked (1393.4 vs 767.4 pg/ml, P¼ 0.02; Table 2).
Comparison of the difference between current smokers and those
who had never smoked did not achieve signiﬁcance (P¼ 0.3),
although levels of TNF- released by current smokers and past
smokers were very similar. Overall, stimulated T lymphocytes from
patients who had ever smoked (pastþ current) released signiﬁ-
cantly more TNF- than those from patients who had never
smoked (1416.0 vs 767.4 pg/ml, P¼ 0.04). Increases in TNF-
release were also observed in unstimulated T cells from past and
current smokers, although these were not signiﬁcant. No associa-
tions were found between monocyte TNF- release and smoking
status.
Smoking and mononuclear cell release
of soluble TNF receptors
Release of soluble TNFRI and TNFRII was detected in all
T-lymphocyte and monocyte cultures. Stimulation with PHA or
LPS had no discernible effect on sTNFRI release, whilst the release
of sTNFRII increased approximately 2-fold for both cell types.
The release of both soluble receptors was correlated with the
release of TNF- in stimulated T lymphocytes (TNF- and
sTNFRI, rS¼ 0.237, P¼ 0.050; TNF- and sTNFRII, rS¼ 0.643,
P<0.0001). No correlations were observed in unstimulated cells,
nor were any correlations observed between the release of TNF-
and soluble receptors in monocytes (data not shown). The levels of
sTNFRI released by both unstimulated and stimulated mono-
nuclear cells showed signiﬁcant correlations with age of the patient
(r 0.39, P 0.001). In the case of sTNFRII, only the levels
released by unstimulated and stimulated T lymphocytes were
correlated with age (r 0.26, P 0.03). No associations were
found with disease duration after adjustment for age.
Differences between groups deﬁned by smoking status were
determined by ANCOVA with correction for age where appro-
priate. Signiﬁcant increases were found in the release of
both sTNFR from stimulated T lymphocytes from past smokers
compared with cells from patients who had never smoked
(P 0.03; Table 3). Release of soluble TNFR by cells from current
smokers showed no differences from the levels released by those
who had never smoked.
In monocytes, no differences were found between groups after
correction for multiple testing, although combining the past and
current smoking groups (ever smoking) revealed a difference in
sTNFRII release between ever and never smoking for unstimu-
lated and stimulated monocytes (P¼ 0.04 and 0.02, respectively).
Influence of smoking on the ratio
of TNF-/sTNFR released by mononuclear cells
Although a history of smoking was associated with an increased
capacity of T lymphocytes to release TNF- and sTNFR after
stimulation, there appeared to be a relatively greater increase in
TNF- release. We were therefore interested to see whether
TABLE 2. Mononuclear cell release of TNF- in RA patients stratiﬁed by
smoking status
Source and smoking status n TNF- release (pg/ml)
Unstimulated T lymphocytes
Never 25 27.6 (62.7)
Past 27 68.3 (201.9)
Current 17 84.9 (168.1)
Stimulated T lymphocytesa
Never 25 767.4 (628.7)
Past 27 1393.4 (1056.7)
Current 17 1451.8 (1630.5)
Unstimulated monocytes
Never 23 1038.5 (2213.7)
Past 28 728.5 (1936.5)
Current 16 998.6 (1863.7)
Stimulated monocytes
Never 23 4908.9 (4598.7)
Past 28 4807.3 (4674.3)
Current 16 5853.4 (6103.3)
Values are mean (S.D.). Kruskal–Wallis ANOVA demonstrated a
signiﬁcant difference between the groups for release of TNF- from
stimulated T lymphocytes (aP¼ 0.02). After correction for multiple
testing (Kruskal–Wallis Z-test), the release of TNF- from stimulated
T cells of past smokers was signiﬁcantly higher than that for never
smokers. There was no signiﬁcant difference between past and current
smokers, and combining these groups revealed a signiﬁcant difference
between ever and never smoking (P¼ 0.04, Mann–Whitney U-test).
TABLE 3. Mononuclear cell release of sTNFRI and sTNFRII in RA
patients stratiﬁed by smoking status
sTNFRI release sTNFRII release
Source and smoking status n (pg/ml) (pg/ml)
Unstimulated T-lymphocytes
Never 25 145.5 (58.0) 449.0 (145.3)
Past 27 182.6 (70.3) 648.4 (296.9)
Current 17 133.0 (53.4) 457.3 (239.3)
Stimulated T-lymphocytesa
Never 25 151.2 (58.9) 834.4 (257.9)
Past 27 188.1 (72.7) 1084.8 (342.0)
Current 17 139.6 (53.7) 838.2 (406.7)
Unstimulated monocytes
Never 23 182.3 (58.3) 1013.7 (260.7)
Past 27 217.9 (69.5) 1219.7 (374.2)
Current 16 175.8 (57.7) 1126.9 (416.4)
Stimulated monocytes
Never 23 187.3 (54.3) 1665.9 (604.6)
Past 27 222.1 (64.5) 2119.4 (882.0)
Current 16 184.9 (56.9) 2036.6 (723.2)
Values are mean (S.D.). There was a signiﬁcant difference between the
groups for release of sTNFRI from stimulated T lymphocytes (aP¼ 0.03,
ANCOVA with adjustment for age). There was also a signiﬁcant
difference between the groups for release of sTNFRII from stimulated
T lymphocytes (aP¼ 0.02, ANCOVA adjusted for age). After correction
for multiple testing, the release of sTNFRI and sTNFRII from the
stimulated T cells of past smokers was signiﬁcantly higher than in those
who had never smoked. In monocytes, no differences were found
between groups. However, combining the past and current smoking
groups (ever smoking) revealed a signiﬁcant difference in sTNFRII
release between ever and never smoking for unstimulated and stimulated
monocytes (P¼ 0.04 and 0.02, respectively).
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smoking status inﬂuenced the relationship between the amounts of
TNF- and sTNFR released by mononuclear cells. Examination of
individual patient TNF-/sTNFRI and TNF-/sTNFRII ratios
revealed that the ratio of TNF-/sTNFRII released from stimu-
lated T lymphocytes was signiﬁcantly higher in both current
and past smokers than in those who had never smoked (1.38 vs
0.86, P¼ 0.03 and 1.25 vs 0.86, P¼ 0.04, respectively). Similar non-
signiﬁcant trends were seen for the TNF-/sTNFRI ratio (data not
shown).
The ratios of TNF-/sTNFRI and TNF-/sTNFRII released
by monocytes did not differ according to smoking status (data not
shown).
Relationship between extent of smoking and
cellular release of TNF- and sTNFR
Information on the number of cigarettes and number of years
smoked was available for 44 of the 46 patients who had ever
smoked. To determine if there was any quantitative relationship
between smoking and TNF- release, we stratiﬁed the extent of
smoking into a number of categories according to length of
smoking history or number of pack years (Table 4). GLM
ANOVA indicated that TNF- production from stimulated
T cells increased with length of smoking history (P for
trend¼ 0.002) and number of pack years (P for trend¼ 0.009).
The signiﬁcance of these associations was altered little by the
inclusion of age, disease duration or current smoking status as
covariates. No relationships between the extent of smoking and
TNF- release by unstimulated T cells or monocytes were found
(data not shown).
Investigation of the relationship between sTNFR release from
stimulated T lymphocytes and categories of smoking duration or
intensity revealed no clear trends (Table 4). Mean TNFRI and
TNFRII release appeared to be greater in all smoking categories
compared with never-smoking, but none were signiﬁcantly
different after adjustment for age and correction for multiple
comparisons. No relationships were found between release of
sTNFRI or RII from monocytes and categories of smoking
duration or intensity (data not shown).
Examination of the TNF-/sTNFR ratios released by stimu-
lated T lymphocytes from patients stratiﬁed by smoking categories
revealed signiﬁcant trends in the relationship between the TNF-/
TNFRI and TNF-/TNFRII ratios and smoking duration
(P for trend¼ 0.01 and 0.0004, respectively), as well as smoking
intensity (P for trend¼ 0.03 and 0.008, respectively) (Table 4).
No relationships were found between TNF-/sTNFR ratios and
smoking categories for monocytes or unstimulated T lymphocytes
(data not shown).
Association between smoking and plasma levels
of TNF- and TNF receptors
No association was found between smoking status and plasma
levels of TNF- (Table 5). However, both sTNFR were found at
higher levels in past smokers than in current smokers, or those who
had never smoked (P 0.01, ANCOVA, age and disease duration
as covariates, with correction for multiple testing). Patients in all
categories for smoking duration and intensity had higher mean
plasma levels of both TNFRI and TNFRII than patients who had
never smoked, but there were no signiﬁcant differences between
categories after adjustment for age and correction for multiple
comparisons (data not shown).
Influence of RF status on the association
of smoking with TNF- and sTNFR release
Since the effects of smoking may be linked to RF production,
analyses were also conducted to assess the inﬂuence of RF status
on the associations observed with smoking. No signiﬁcant
differences in mononuclear cell release of TNF- and sTNFR
were observed between RF positive and RF-negative smokers
(data not shown). The association of smoking with the increased
TNF-/sTNFRII ratio released from T lymphocytes was also
independent of RF status.
Discussion
We report that TNF- release by stimulated T lymphocytes from
peripheral blood was greater in RA patients with a history of
TABLE 4. Levels of TNF- and TNFR released by stimulated T lymphocytes from patients stratiﬁed by smoking duration and intensity
n TNF- (pg/ml) TNFRI (pg/ml) TNFRII (pg/ml) TNF/TNFRI ratio TNF/TNFRII ratio
Duration (yr)
0 25 767.4 (628.7) 151.2 (58.9) 834.4 (257.9) 5.83 (5.31) 0.86 (0.53)
1–14 10 820.7 (763.2) 174.5 (68.0) 1034.3 (446.0) 4.50 (3.54) 0.74 (0.56)
15–29 15 1391.4 (1270.0) 156.1 (63.7) 931.5 (333.9) 7.37 (4.50) 1.32 (0.83)
30 19 1748.7 (1445.4) 177.1 (74.7) 1011.8 (400.0) 10.61 (9.66) 1.59 (0.91)
Intensity (pack years)
0 25 767.4 (628.7) 151.2 (58.9) 834.4 (257.9) 5.83 (5.31) 0.86 (0.53)
1–14 16 1294.7 (1350.3) 181.6 (74.9) 1051.9 (422.1) 5.68 (5.17) 1.09 (0.95)
15–29 12 1282.5 (896.0) 159.3 (48.4) 907.0 (380.8) 8.14 (6.60) 1.29 (0.67)
30 16 1637.4 (1509.7) 164.7 (73.1) 989.1 (356.9) 10.43 (9.25) 1.53 (0.90)
Values are mean (S.D.). Analyses were by GLM implementation of ANOVA or ANCOVA. TNF- release increased with smoking duration (P for
trend¼ 0.002) and intensity (P for trend¼ 0.009). Inclusion of age, disease duration and current smoking status as covariates made little or no
difference to the signiﬁcance of the associations. There were no signiﬁcant trends in the relationship between sTNFR release and categories of smoking
duration or intensity. Signiﬁcant trends were seen in the relationship between TNF-/TNFRI and TNF-/TNFRII ratios and smoking duration (P for
trend¼ 0.01 and 0.0004, respectively), as well as smoking intensity (P for trend¼ 0.03 and 0.008, respectively).
TABLE 5. Levels of TNF- and soluble TNF receptors in plasma of RA
patients stratiﬁed by smoking status
Smoking status
Plasma cytokine Never (n¼ 25) Past (n¼ 29) Current (n¼ 17)
TNF- (pg/ml) 257.0 (809.0) 328.3 (1231.6) 655.8 (1886.8)
sTNFRI (pg/ml) 1103.2 (411.8) 1489.7 (577.3) 976.1 (329.1)
sTNFRII (pg/ml) 4139.2 (1541.4) 5860.0 (2212.8) 4255.9 (1968.6)
Values are mean (S.D.). No signiﬁcant differences were found between
groups for plasma levels of TNF-. ANCOVA (age and disease duration
as covariates) with correction for multiple testing demonstrated that past
smokers had signiﬁcantly higher levels of sTNFRI and sTNFRII than
current smokers and patients that had never smoked (P 0.01).
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smoking than in those who had never smoked. This suggests that
the effects of smoking, either directly or indirectly, may include the
priming of circulating T lymphocytes for enhanced TNF- release
when appropriately challenged. Other studies in healthy individ-
uals have shown that TNF- release by PBMCs is increased in
smokers [19, 20], although T lymphocyte and monocyte popula-
tions were not investigated separately. In our study the effects
of smoking on TNF- release appeared to be restricted to
T lymphocytes, since no signiﬁcant difference in TNF- release
by monocytes was observed between smokers and non-smokers.
This was unexpected since monocytes/macrophages are the major
cellular source of TNF-. The lack of association between smoking
and plasma TNF- levels in this study probably reﬂects the absence
of an association between smoking and monocyte TNF- release.
However, T lymphocytes are also an important source of TNF-
when activated, and can produce signiﬁcant amounts of this
cytokine. The reason for the apparent cell-speciﬁcity in the
association of TNF- release with smoking is not clear, but
suggests possible differences in the response of T lymphocytes and
monocytes to components of cigarette smoke.
A number of studies have investigated the effect of nicotine on
cytokine production in whole mononuclear cell populations from
peripheral blood of healthy subjects. Nicotine at low concentra-
tions was shown to stimulate TNF- secretion [20], but at levels
equivalent to that in the plasma of smokers it inhibited TNF- and
IL-2 production [21]. Another study investigating the effects of
nicotine patch treatment found diminished production of IL-10
as well as TNF- and IL-2 production by PHA-stimulated
non-adherent mononuclear cells [39]. The cholinergic/nicotinic
anti-inﬂammatory pathway recently described by Wang et al.
may explain such ﬁndings [40]. Wang et al. demonstrated that
activation of 7 nicotinic acetylcholine receptors (nAChRs) on
macrophages by cholinergic agonists such as acetylcholine and
nicotine reduces the release of TNF- and other proinﬂammatory
cytokines induced by LPS. The presence of 7 nicotinic receptors
on lymphocytes has also been demonstrated [41]. One might have
expected therefore that mononuclear cells isolated from current
smokers would show diminished TNF- release because of recent
exposure to nicotine. However, our ﬁndings indicate that any
inhibitory effect of recent nicotine exposure is not evident in
isolated mononuclear cells from RA patients who are current
smokers. The ﬁnding that TNF- release from stimulated
T lymphocytes is equally elevated in past as well as current
smokers also argues against an effect due to recent nicotine
exposure.
Clearly, nicotine is only one of many components of cigarette
smoke that might inﬂuence cellular responses, and water-soluble
extracts of cigarette smoke have been shown to stimulate TNF-
release from human blood monocytes [42]. It might have been
anticipated that any effects of smoking would be greatest in current
smokers where the toxic components of cigarette smoke are
present. However, the levels of TNF- released by stimulated
T lymphocytes of past smokers were no different to those
of current smokers, and up to 15 yr after smoking cessation they
were signiﬁcantly greater than those released by non-smokers
(JR Glossop and DL Mattey unpublished observations). Our data
indicate that the length of smoking history is more important than
whether or not a patient is currently smoking. This suggests that
increased TNF- release from stimulated T cells may be a
prolonged, chronic response that may last for many years after
smoking cessation. This could be a result of long-term biological
changes which might occur through alterations in T-cell phenotype
and/or changes in the proportions of particular T-cell subsets.
Smoking also appears to inﬂuence the release of both TNF
receptors from stimulated T lymphocytes, although, in contrast to
TNF- release, there was no apparent relationship between the
extent of smoking and the level of sTNFR release. Again there was
an indication that the effects of smoking may last long after
smoking cessation, since the highest levels released were found in
past smokers. The highest circulating levels were also found in past
smokers. Current smokers in this study did not show an increase
in sTNFR levels, although in other studies on young healthy
diabetics and healthy smokers current smoking has been associated
with increases in plasma TNFR levels [43, 44].
The lack of a clear relationship between sTNFR levels and the
extent of smoking suggests the possibility of some other factor
having a confounding affect on receptor levels in past smokers with
RA. For example, some individuals may have given up smoking
because they associated it with worsening disease, while those who
continued to smoke might have done so because it did not
apparently inﬂuence their condition. Other factors that might
determine whether a patient continues to smoke include the
development of comorbid disease (e.g. heart disease) or particular
genetic polymorphisms. The latter could play a part, for example,
in determining smoking persistence and/or levels of sTNFR.
We have shown previously that the level of sTNFR released by
T cells fromRA patients is associated with polymorphism (T676G)
in the TNFRII gene [37]. However, multiple regression analysis
on data from this study indicated that the association of TNFR
release with past smoking was independent of TNFRII genotype
(JR Glossop and DL Mattey unpublished observations).
Of particular interest was the ﬁnding that the ratio of TNF-/
sTNFR released from stimulated T lymphocytes was increased
in smokers. There were also signiﬁcant relationships between the
extent of smoking and the TNF-/sTNFR ratios. This reﬂects
an increase in TNF- release with increased extent of smoking,
relative to little or no change in TNFR release. This alteration in
the balance between TNF- and TNF receptor release appears
to be retained after smoking cessation. We speculate that this
imbalance would be likely to promote increased TNF- activity
and may better reﬂect the inﬂuence of smoking on the TNF- axis.
Further studies are needed to determine whether smoking causes
differential synthesis and/or turnover of TNF- and its receptors,
or whether smoking has differential effects on cleavage of TNF-
and its receptors through effects on TACE and other possible
sheddases. A recent report by Shao et al. [45] implicates TACE in
some of the cellular responses to smoking. These authors found,
in a human airway epithelial cell line, that the effects of cigarette
smoke on transforming growth factor- shedding, epidermal
growth factor receptor phosphorylation and mucin expression
were prevented by a TACE inhibitor and by speciﬁc knockdown
of TACE with small interferins RNA. The study suggested that
oxygen free radicals were responsible for the activation of TACE
by cigarette smoke.
In conclusion, our results indicate that there is an association
between smoking and the release of TNF- and soluble TNFR by
PBMCs fromRA patients. In particular, stimulated T lymphocytes
from patients with a history of smoking released signiﬁcantly
greater levels of TNF- than did cells from patients who had never
smoked, and this was related to the extent of smoking. The data
suggest that smoking causes an imbalance in the ratio of TNF-/
sTNFR released by stimulated T cells that might favour increased
TNF- activity. Our ﬁndings may be of particular relevance to
preliminary reports that RA patients who smoke are more likely to
receive a biological agent [46], and that smoking is associated with











 In RA patients who smoke there is an
increase in the ratio of TNF-/sTNFR
released by stimulated T lymphocytes.
 The increased TNF-/sTNFR ratio is
associated with extent of smoking, and
remains elevated after smoking cessation.
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